Pirfenidone Inhibits Dimethylnitrosamine-Induced Hepatic Fibrosis In Rats

Authors: Tada, Seiya1; Nakamuta, Makoto1; Enjoji, Munechika1; Sugimoto, Rie1; Iwamoto, Hiroaki1; Kato, Masaki1; Nakashima, Yutaka; Nawata, Hajime1

Source: Clinical and Experimental Pharmacology and Physiology, Volume 28, Number 7, July 2001 , pp. 522-527(6)

Publisher: Blackwell Publishing

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

SUMMARY

1. In the present study, we investigated the preventive effects of pirfenidone (PFD), an antifibrotic agent, on experimental hepatic fibrosis induced by dimethylnitrosamine (DMN) in rats.

2. Treatment with DMN caused a significant decrease in bodyweight and liver weight. Oral PFD (500 mg/kg daily for 4 weeks) essentially prevented this DMN-induced loss in bodyweight and tended to suppress the loss in liver weight. There were no significant differences in liver weight and serumL-alanine aminotransferase levels between PFD-treated and -untreated groups. Pirfenidone has no major side effects in vivo.

3. Pirfenidone suppressed the induction of hepatic fibrosis determined by histological evaluation and reduced hepatic hydroxyproline levels. Expression of mRNA for type I collagen and transforming growth facter-β in the liver was also suppressed by PFD treatment.

4. Because hepatic stellate cells (HSC) are the major cellular source of extracellular matrix in hepatic fibrosis, we examined the effects of PFD on type I collagen production in vitro using rat primary HSC cultures. Pirfenidone inhibited collagen production in HSC culture in a dose-dependent manner.

5. These results demonstrate that the inhibitory effects of PFD against hepatic fibrosis may be due, at least in part, to blockade of collagen production by HSC and suggest that PFD may be potentially useful in the prevention of the development of hepatic fibrosis.

Keywords: dimethylnitrosamine; hepatic fibrosis; hepatic stellate cells; hydroxyproline; pirfenidone; type I collagen

Document Type: Research article

DOI: 10.1046/j.1440-1681.2001.03481.x

Affiliations: 1: Department of Medicine and Bioregulatory Science and

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.16 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A